Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) - BeOne

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

BeOne Study ID

BGB-3111-206

ClinicalTrials.gov ID

NCT03206970

China Drug Trials ID

CTR20160888

Study Overview

Sex: All

Age: 18 Years / 75 Years

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / 75 Years

Study Documents

Study Protocol Statistical Analysis Plan